The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Expands bioprocessing footprint across Asia
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Subscribe To Our Newsletter & Stay Updated
